Compare CCB & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCB | COLL |
|---|---|---|
| Founded | 1997 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2018 | 2015 |
| Metric | CCB | COLL |
|---|---|---|
| Price | $74.19 | $32.42 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $126.67 | $51.17 |
| AVG Volume (30 Days) | 133.3K | ★ 547.7K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.06 | 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $96.61 | $5.93 |
| Revenue Next Year | $22.66 | N/A |
| P/E Ratio | $24.43 | ★ $19.32 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $70.72 | $23.23 |
| 52 Week High | $120.05 | $50.79 |
| Indicator | CCB | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 35.92 | 24.32 |
| Support Level | $70.72 | $31.01 |
| Resistance Level | $118.72 | $32.92 |
| Average True Range (ATR) | 2.60 | 1.30 |
| MACD | 0.52 | -0.04 |
| Stochastic Oscillator | 5.08 | 1.07 |
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.